Bank of New York Mellon’s Harvard Bioscience HBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$62.9K Hold
10,230
﹤0.01% 4224
2026
Q1
$49.8K Sell
10,230
-2,392
-19% -$13.4K ﹤0.01% 4143
2025
Q4
$84.4K Hold
12,622
﹤0.01% 4113
2025
Q3
$55.3K Hold
12,622
﹤0.01% 4125
2025
Q2
$56K Sell
12,622
-8,333
-40% -$34.8K ﹤0.01% 4083
2025
Q1
$119K Hold
20,955
﹤0.01% 3982
2024
Q4
$442K Sell
20,955
-2,053
-9% -$47.2K ﹤0.01% 3587
2024
Q3
$619K Sell
23,008
-4,456
-16% -$131K ﹤0.01% 3396
2024
Q2
$783K Buy
27,464
+3,151
+13% +$111K ﹤0.01% 3330
2024
Q1
$1.03M Sell
24,313
-648
-3% -$29.1K ﹤0.01% 3134
2023
Q4
$1.34M Buy
24,961
+2,261
+10% +$102K ﹤0.01% 3039
2023
Q3
$976K Buy
22,700
+276
+1% +$12.7K ﹤0.01% 3163
2023
Q2
$1.23M Buy
22,424
+8,969
+67% +$492K ﹤0.01% 3085
2023
Q1
$565K Hold
13,455
﹤0.01% 3431
2022
Q4
$373K Sell
13,455
-2,875
-18% -$70.9K ﹤0.01% 3697
2022
Q3
$419K Sell
16,330
-473
-3% -$15.6K ﹤0.01% 3666
2022
Q2
$605K Sell
16,803
-9,828
-37% -$444K ﹤0.01% 3470
2022
Q1
$1.65M Buy
26,631
+1,816
+7% +$107K ﹤0.01% 3040
2021
Q4
$1.75M Buy
24,815
+2,883
+13% +$205K ﹤0.01% 3072
2021
Q3
$1.53M Buy
21,932
+1,597
+8% +$127K ﹤0.01% 3162
2021
Q2
$1.69M Buy
20,335
+4,559
+29% +$323K ﹤0.01% 3104
2021
Q1
$862K Buy
15,776
+4,679
+42% +$228K ﹤0.01% 3417
2020
Q4
$476K Sell
11,097
-241
-2% -$8.99K ﹤0.01% 3642
2020
Q3
$341K Buy
11,338
+145
+1% +$4.88K ﹤0.01% 3668
2020
Q2
$347K Buy
11,193
+9,790
+698% +$264K ﹤0.01% 3645
2020
Q1
$31K Hold
1,403
﹤0.01% 4018
2019
Q4
$43K Hold
1,403
﹤0.01% 4123
2019
Q3
$43K Hold
1,403
﹤0.01% 4135
2019
Q2
$28K Sell
1,403
-9,587
-87% -$281K ﹤0.01% 4169
2019
Q1
$473K Sell
10,990
-76
-0.7% -$2.75K ﹤0.01% 3582
2018
Q4
$352K Buy
11,066
+801
+8% +$31.6K ﹤0.01% 3647
2018
Q3
$539K Sell
10,265
-1,614
-14% -$90.6K ﹤0.01% 3615
2018
Q2
$636K Buy
11,879
+7,662
+182% +$392K ﹤0.01% 3503
2018
Q1
$211K Buy
4,217
+578
+16% +$25.9K ﹤0.01% 3919
2017
Q4
$120K Sell
3,639
-44
-1% -$1.49K ﹤0.01% 4052
2017
Q3
$138K Hold
3,683
﹤0.01% 3942
2017
Q2
$94K Sell
3,683
-116
-3% -$2.87K ﹤0.01% 4039
2017
Q1
$99K Buy
3,799
+116
+3% +$3.34K ﹤0.01% 4033
2016
Q4
$113K Sell
3,683
-223
-6% -$5.67K ﹤0.01% 4011
2016
Q3
$106K Sell
3,906
-1,119
-22% -$31.1K ﹤0.01% 4025
2016
Q2
$144K Sell
5,025
-6,192
-55% -$197K ﹤0.01% 3974
2016
Q1
$338K Buy
11,217
+149
+1% +$4.22K ﹤0.01% 3596
2015
Q4
$384K Buy
11,068
+129
+1% +$4.41K ﹤0.01% 3631
2015
Q3
$413K Sell
10,939
-2,871
-21% -$134K ﹤0.01% 3666
2015
Q2
$787K Buy
13,810
+9,627
+230% +$548K ﹤0.01% 3466
2015
Q1
$243K Hold
4,183
﹤0.01% 3843
2014
Q4
$237K Hold
4,183
﹤0.01% 3849
2014
Q3
$171K Sell
4,183
-804
-16% -$37K ﹤0.01% 3925
2014
Q2
$227K Sell
4,987
-8,437
-63% -$355K ﹤0.01% 3804
2014
Q1
$636K Sell
13,424
-1,084
-7% -$49.3K ﹤0.01% 3494
2013
Q4
$682K Sell
14,508
-8,920
-38% -$390K ﹤0.01% 3466
2013
Q3
$935K Buy
23,428
+3,725
+19% +$146K ﹤0.01% 3281
2013
Q2
$701K Buy
+19,703
New +$754K ﹤0.01% 3362

Other funds holding HBIO

Bank of New York Mellon's HBIO Position: Q2 2026 in Review

Bank of New York Mellon held its Harvard Bioscience (HBIO) position steady in Q2 2026 at 10,230 shares worth $62.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4224.

Bank of New York Mellon first reported a position in HBIO in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.75M in Q4 2021. 13 funds tracked by Wall St. Rank hold HBIO as of Q2 2026.

  • Bank of New York Mellon held 10,230 shares of Harvard Bioscience worth $62.9K as of Q2 2026.
  • Bank of New York Mellon left its Harvard Bioscience share count unchanged in Q2 2026.
  • Harvard Bioscience made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #4224 holding.
  • Bank of New York Mellon first reported a position in Harvard Bioscience in Q2 2013 and has held it in 53 quarters since.
  • Bank of New York Mellon's Harvard Bioscience position peaked at $1.75M in Q4 2021.
  • 13 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.